[1] Gower E,Estes C,Blach S,et al.Global epidemiology and genotype distribution of the hepatitis C virus infection.J Hepatol,2014,61:S45-57.
[2] Niederau C,Huppe D,Zehnter E,et al.Chronic hepatitis C:treat or wait Medical decision making in clinical practice.World J Gastroenterol,2012,18:1339-1347.
[3] Chung RT,Baumert TF.Curing chronic hepatitis C--the arc of a medical triumph.N Engl J Med,2014,370:1576-1578.
[4] Pawlotsky JM.Hepatitis C treatment:the data flood goes on-an update from the liver meeting 2014.Gastroenterology,2015,148:468-479.
[5] Sarrazin C.The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.J Hepatol,2016,64:486-504.
[6] Pawlotsky JM.Hepatitis C virus population dynamics during infection.Curr Top Microbiol Immunol,2006,299:261-284.
[7] Neumann AU,Lam NP,Dahari H,et al.Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.Science,1998,282:103-107.
[8] Pawlotsky JM.New hepatitis C virus(HCV)drugs and the hope for a cure:concepts in anti-HCV drug development.Semin Liver Dis,2014,34:22-29.
[9] Pawlotsky JM.Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.Hepatology,2011,53:1742-1751.
[10] Pawlotsky JM.Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens.Gastroenterology,2016,151:70-86.
[11] Lindenbach BD,Rice CM.Unravelling hepatitis C virus replication from genome to function.Nature,2005,436:933-938.
[12] Romano KP,Ali A,Aydin C,et al.The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.PLoS Pathog,2012,8:e1002832.
[13] Schinazi R,Halfon P,Marcellin P,et al.HCV direct-acting antiviral agents:the best interferon-free combinations.Liver Int,2014,34 Suppl 1:69-78.
[14] Welsch C,Jesudian A,Zeuzem S,et al.New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.Gut,2012,61 Suppl 1:i36-46.
[15] Sullivan JC,De Meyer S,Bartels DJ,et al.Evolution of treatmentemergent resistant variants in telaprevir phase 3 clinical trials.Clin Infect Dis,2013,57:221-229.
[16] Lenz O,Verbinnen T,Lin TI,et al.In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.Antimicrob Agents Chemother,2010,54:1878-1887.
[17] Jacobson IM,Dore GJ,Foster GR,et al.Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1):a phase 3,randomised,double-blind,placebo-controlled trial.Lancet,2014,384:403-413.
[18] Forns X,Lawitz E,Zeuzem S,et al.Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy:a phase 3 trial.Gastroenterology,2014,146:1669-1679 e1663.
[19] Manns M,Pol S,Jacobson IM,et al.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:a multinational,phase 3,multicohort study.Lancet,2014,384:1597-1605.
[20] Poordad F,Hezode C,Trinh R,et al.ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.N Engl J Med,2014,370:1973-1982.
[21] Feld JJ,Kowdley KV,Coakley E,et al.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.N Engl J Med,2014,370:1594-1603.
[22] Lawitz E,Sulkowski M,Jacobson I,et al.Characterization of vaniprevir,a hepatitis C virus NS3/4A protease inhibitor,in patients with HCV genotype 1 infection:safety,antiviral activity,resistance,and pharmacokinetics. Antiviral Res,2013,99:214-220.
[23] McGivern DR,Masaki T,Williford S,et al.Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.Gastroenterology,2014,147:453-462 e457.
[24] Gao M.Antiviral activity and resistance of HCV NS5A replication complex inhibitors.Curr Opin Virol,2013,3:514-520.
[25] Nelson DR,Cooper JN,Lalezari JP,et al.All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALLY-3 phase III study.Hepatology,2015,61:1127-1135.
[26] Afdhal N,Zeuzem S,Kwo P,et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med,2014,370:1889-1898.
[27] Zeuzem S,Jacobson IM,Baykal T,et al.Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.N Engl J Med,2014,370:1604-1614.
[28] Joyce CM,Steitz TA.Polymerase structures and function:variations on a theme J Bacteriol,1995,177:6321-6329.
[29] Gerber L,Welzel TM,Zeuzem S.New therapeutic strategies in HCV:polymerase inhibitors.Liver Int,2013,33 Suppl 1:85-92.
[30] Gane EJ,Stedman CA,Hyland RH,et al.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.N Engl J Med,2013,368:34-44.
[31] Zeuzem S,Dusheiko GM,Salupere R,et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3.N Engl J Med,2014,370:1993-2001.
[32] Donaldson EF,Harrington PR,O＇Rear JJ,et al.Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.Hepatology,2015,61:56-65.
[33] Everson GT,Sims KD,Rodriguez-Torres M,et al.Efficacy of an interferon-and ribavirin-free regimen of daclatasvir,asunaprevir,and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.Gastroenterology,2014,146:420-429.
[34] Hezode C,Chevaliez S,Scoazec G,et al.Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.Hepatology,2016,63:1809-1816. |
